EHA 2023 | Heterogeneity in treatment preferences of patients with R/R multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, comments on a study evaluating the heterogeneity in treatment preferences in patients with relapsed/refractory (R/R) multiple myeloma. The study found that whilst all patients wanted to maximize treatment efficacy and reduce toxicity, there were distinct groups of patients with different expectations in relation to their treatment – some prioritized maximizing response rates, while others prioritized maximizing survival rates, or were interested in the mode of delivery of the treatment. Dr Popat explains that despite the efficacy of CAR-T therapy, many patients were concerned about the toxicity of this therapy, and thus emphasizes the important role of healthcare professionals (HCP) in communicating the high efficacy of this treatment modality to patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
